Development of blood tests for early detection and treatment monitoring of cervical cancer
Not Applicable
- Conditions
- Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
- Registration Number
- CTRI/2020/01/022862
- Lead Sponsor
- DBT Ramalingaswamy Fellowship
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Inclusion criteria includes Patients 18 years old or older with suspicion of cervical cancer referred to Manipal Comprehensive Cancer Center.
Exclusion Criteria
Patients diagnosed with inflammatory or haematological disease after the age of 18 will be excluded from the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. The primary outcome is to measure the percentage of cervical cancers that can be detected using a liquid biopsy. Samples from follow up timepoints will be useful for analysis of treatment and their prognostic value for success of brachytherapy. <br/ ><br>2.Measure recurrence in cervical cancer patients through serial monitoring with liquid biopsies (blood sample). <br/ ><br>3.Identification of novel cervical cancer susceptible genes or genetic markers in the Indian population.Timepoint: 0, 3, 6 months. Follow up at 36 months.
- Secondary Outcome Measures
Name Time Method Identification of novel cervical cancer susceptible genes or genetic markers in the Indian population.Timepoint: Pretreatment sample